Skip to main content

Table 5 Comparison between survivors and non-survivors at 6 months

From: Prognostic implications of IDH1rs11554137 and IDH2R140Q SNPs mutations in cytogenetically normal acute myeloid leukemia

  

Survivors

(N = 33, 41.3%)

Died

(N = 47, 58.7%)

p value*#

Age (years)

Mean ± SD

38.8 ± 10.7

49.2 ± 17.7

0.004

Gender

N (%)

  

0.077

 Male

 

24 (72.7)

25 (53.2)

 

 Female

 

9 (27.3)

22 (46.8)

 

Hepatomegaly

N (%)

  

0.429

 Negative

 

16 (48.5)

27 (57.4)

 

 Positive

 

17 (51.5)

20 (42.6)

 

Splenomegaly

N (%)

   

 Negative

 

12 (36.4)

17 (36.2)

1.000

 Positive

 

21 (63.6)

30 (63.8)

 

Lymphadenopathy

N (%)

  

0.537

 Negative

 

21 (63.6)

33 (70.2)

 

 Positive

 

12 (36.4)

14 (29.8)

 

Hemoglobin (g/dl)

Mean ± SD

6.3 ± 2.5

7.1 ± 1.6

0.085

TLC (× 109/L)

Mean ± SD

72.4. ± 34.5

66.6 ± 46.5

0.545

Platelets (× 109/L)

Mean ± SD

24.2 ± 9.5

33.5 ± 20.1

0.016

Blast cells (%)

Mean ± SD

65.4 ± 17.8

76.9 ± 13.6

0.002

FAB classification

N (%)

  

0.082

 M1

 

3 (9.1)

9 (19.1)

 

 M2

 

16 (48.5)

28 (59.6)

 

 M4

 

12 (36.4)

6 (12.8)

 

 M5

 

2 (6.1)

4 (8.5)

 

IDH1SNPrs11554137

N (%)

  

0.003

 Normal

 

33 (100)

36 (76.6)

 

 Heterozygous

 

0 (0)

11 (23.4)

 

IDH2R140Q

N (%)

  

0.146

 Normal

 

30 (91.3)

37 (78.7)

 

 Heterozygous

 

3 (9.1)

10 (21.3)

 
  1. N number, SD standard deviation, TLC total leucocytic count, IQR interquartile range
  2. *Unpaired t test for quantitative data with parametric distribution
  3. #Chi-square test for qualitative data
  4. Fisher’s exact test when the expected count in any cell was found at less than 5
  5. A p value <0.05 was considered the cut-off value for significance in all analyses